Centrus Grew Revenue 14% by Reselling Uranium While Its Enrichment Volumes Fell 23%
Hypothesis Opus 5 · Research Opus 5 · Writing Opus 5 · Prompt v1.5
The August rally in nuclear fuel stocks is being sold as scarcity of Western enrichment capacity. Centrus Energy, the only US-owned commercial enricher, is the purest way to own that scarcity — and its own second quarter shows the scarcity has not yet reached its income statement. Separative work unit volumes fell 23% year over year while enrichment pricing rose 3%; revenue still grew 14% because the company resold more natural uranium at lower margins. Gross profit fell 7.4%, operating income fell 69%.
The month's gains went to the uranium miners — Cameco, Uranium Energy — not to the pre-revenue reactor developers Oklo and NuScale, and they came against a 19-year high in the 30-year Treasury yield. Cameco now costs 64.2x trailing gross profit, up from 60.3x in May, after that gross profit fell a third. BWX Technologies raised every guidance line and sits at a 52-week low.
| Ticker | Company | Segment | Trend · 13mo | 30D | 1Y |
|---|---|---|---|---|---|
| The subject · what this brief is about | |||||
LEU | Centrus Energy | Uranium | ⚠️ Emerging Bear | +9.8% | −0.1% |
CCJ | Cameco | Uranium | ⚠️ Emerging Bear | +14.8% | +37.1% |
BWXT | BWX Technologies | Naval & Shipbuilding | ⚠️ Emerging Bear | −11.3% | −3.6% |
| Compared against · context, not the story | |||||
UEC | Uranium Energy | Uranium | ⚠️ Emerging Bear | +26.2% | +13.2% |
OKLO | Oklo | Emerging & Specialized Energy | 🔴 Cont. Bear | +7.2% | −39.7% |
SMR | NuScale Power | Advanced Nuclear | 🔴 Cont. Bear | +13.3% | −73.4% |
NXE | NexGen Energy | Uranium | ⚠️ Emerging Bear | +15.5% | +49.4% |
URA | Global X - Uranium ETF | Asset Management | ⚠️ Emerging Bear | +16.3% | +20.3% |
DNN | Denison Mines | Uranium | ⚠️ Emerging Bear | +22.7% | +62.3% |
12-month price & trend
| Ticker | Mkt cap | P/E | P/E fwd | P/S | P/S fwd | P/GP | P/GP fwd | EV/EBITDA | FCF yld |
|---|---|---|---|---|---|---|---|---|---|
LEU | $3.5B | 74.2x | 74.6x | 7.4x | 7.6x | 32.0x | 32.5x | 39.1x | -6.3% |
CCJ | $44.6B | 172.7x | 66.4x | 17.7x | 12.5x | 64.2x | 45.2x | 71.2x | 0.8% |
BWXT | $14.4B | 40.4x | 33.1x | 4.1x | 3.8x | 18.5x | 17.1x | 28.5x | 2.2% |
| Ticker | Mkt cap | P/E | P/E fwd | P/S | P/S fwd | P/GP | P/GP fwd | EV/EBITDA | FCF yld |
|---|---|---|---|---|---|---|---|---|---|
UEC | $5.5B | n/m | — | 274.6x | 55.3x | 648.9x | 130.6x | n/m | -2.2% |
OKLO | $7.2B | n/m | — | — | — | — | — | n/m | -3.8% |
SMR | $2.8B | n/m | — | 261.9x | 91.1x | — | 432.7x | n/m | -27.7% |
| Ticker | Mkt cap | P/E | P/E fwd | P/S | P/S fwd | P/GP | P/GP fwd | EV/EBITDA | FCF yld |
|---|---|---|---|---|---|---|---|---|---|
NXE | $7.0B | n/m | — | n/m | — | — | — | n/m | -2.5% |
URA | $3.9B | — | — | — | — | — | — | — | — |
DNN | $2.9B | n/m | — | 988.4x | 120.1x | — | — | n/m | -4.1% |
Consensus projections
| Ticker | FY2026E | FY2027E | FY2028E | |
|---|---|---|---|---|
LEU | Revenue | +4.3% | +1.0% | −10.1% |
| EPS | −44.3% | +14.9% | −15.1% | |
CCJ | Revenue | +4.5% | +10.7% | +6.8% |
| EPS | +7.6% | +70.8% | +25.1% | |
BWXT | Revenue | +20.6% | +9.6% | +7.4% |
| EPS | +24.1% | +11.1% | +11.9% | |
UEC | Revenue | −59.3% | +272.6% | +157.9% |
| EPS | +58.7% | −79.8% | −647.6% | |
OKLO | Revenue | — | +247.3% | +577.4% |
| EPS | +50.0% | +10.3% | +16.5% | |
SMR | Revenue | −26.7% | +434.9% | +101.2% |
| EPS | −74.7% | +33.4% | −18.3% | |
NXE | Revenue | −68.7% | +131.4% | +32282.1% |
| EPS | −38.6% | −10.8% | +37.8% | |
DNN | Revenue | +394.2% | −27.3% | +1699.7% |
| EPS | −30.5% | −73.1% | −363.0% |
Forward fiscal years only. Blank means no analyst coverage for that year.
Centrus Energy exists to enrich uranium. In the three months to June it did less of that than a year earlier — separative work unit (SWU) volumes fell 23% — and still reported revenue growth of 14%, to $176.1m, because it resold more natural uranium to utilities at slimmer margins. Enrichment pricing rose 3% over the year. Cost of sales in the low-enriched uranium (LEU) segment rose 36%. Gross margin fell to 28.3% from 34.9%, gross profit fell 7.4% to $49.9m, and operating income fell 69% to $10.4m.
That matters because the entire re-rating of this corner of the market rests on a physical bottleneck. Enrichment sells for roughly $160 per SWU today against about $40 before 2022, a 167% rise driven by a US ban on Russian enriched uranium that becomes a full prohibition in 2028 — against a Western capacity base that cannot meaningfully expand before then. Centrus, headquartered in Bethesda, Maryland, is the only US-owned commercial enricher and the only listed pure play on that squeeze. Its backlog now stands at $4.5bn stretching to 2040, of which $3.7bn is enrichment and uranium sales and $2.4bn sits under definitive agreements rather than contingent terms. A $900m Department of Energy task order is excluded from that figure.
The backlog is real. The earnings are going the other way. Consensus has Centrus earning $2.50 a share this year against $3.90 delivered in 2025, and the capital to build the Piketon, Ohio, plant is coming partly from shareholders: diluted shares have gone from 16.4m to 21.9m in eight quarters, roughly 33% dilution, with $53.9m raised through the at-the-market program last quarter alone. Capex guidance of $350-500m for 2026 brackets the revenue guidance of $450-500m. Free cash flow yield is -6.3%.
The month belonged to the pounds, not the reactors
From 22 July to 21 August the gains ran through the miners. Uranium Energy Corp, a US developer that booked no revenue at all last quarter against a $40.8m operating loss, rose 22.5%. Cameco, the world's largest listed uranium producer, rose 13.4%. Centrus rose 6.9%. The two pre-revenue reactor developers did not participate: NuScale Power, whose small modular design is the only one with US regulatory certification, gained 7.3% on quarterly revenue that fell to $75,000 from $8.05m; Oklo, developer of the Aurora powerhouse, fell 4.7% despite holding $3bn of cash.
This was not a discount-rate rally either. The 30-year Treasury yield topped 5.33% on 18 August, a 19-year high. Three days later, at the Global 2026 conference, Urenco USA said it would expand American enrichment capacity by nearly 50% with a new plant, and Ur-Energy shipped its first uranium from Shirley Basin. Cameco closed up 7.24% that session, Centrus up 5.75% — Centrus rising, notably, on news that its scarcity is being addressed by a competitor. Spot uranium was $88.29 a pound on 20 August, little changed since February, while the long-term contract price reached $90 in the first quarter, its highest since 2008.
Cameco got more expensive as it earned less
Cameco's second quarter went backwards. Revenue fell 7.2% to $814.1m, gross margin fell to 21.1% from 29.3%, and gross profit fell a third. The swing factor was Westinghouse Electric, 49%-owned by Cameco, which reported a $10m net loss on Cameco's share against $126m of earnings a year earlier; Westinghouse has confidentially filed for a US listing. Production guidance of 19.5-21.5 million pounds was left intact.
The price paid for that stream has widened. Cameco costs 64.2x trailing gross profit today against 60.3x in May, having fallen from 72.0x in February — the multiple re-expanded over three months while the profit underneath it shrank. Forward earnings multiple: 66.4x.
BWX Technologies is the reverse. It builds the US Navy's nuclear reactors and fuel on a sole-source basis and makes commercial reactor vessels and TRISO fuel. Revenue grew 18% to $901.6m, backlog reached $8.4bn, up 40%, and on 3 August it raised every 2026 guidance line, including adjusted earnings to $4.70-4.80 a share. The shares fell 10.5% over the month to a 52-week low. Its price per dollar of trailing gross profit has compressed from 25.9x in February to 18.5x — a 28% de-rating while that gross profit grew 6%.
Cameco and BWXT have both traded with their 50-day average below their 200-day since early July. Centrus emerged from that condition on 12 August. On the numbers, the ranking is inverted: the cheapest business is the one growing fastest.
The setup
Where it stands — Enrichment scarcity is being priced into Centrus and Cameco while the only member with rising backlog and raised guidance, BWXT, sits at a 52-week low. Would confirm — Centrus third-quarter SWU volumes returning to growth with enrichment pricing up more than 3% year over year. Would invalidate — Centrus 2026 revenue landing below the $450m guidance floor, or Cameco cutting its 19.5-21.5 million pound production range. Watch next — Centrus and Cameco third-quarter results, early November; the Westinghouse listing terms whenever the S-1 goes public. Valuation — Centrus at 32.0x trailing and 32.5x forward gross profit, versus 32.9x in February; Cameco 64.2x, BWXT 18.5x.















































































































